Saturday, 31 October 2026European Markets

SOLSTAD OFFSHORE Stock Bullish By 33% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of SOLSTAD OFFSHORE (Oslo Børs All-share Index_GI: SOFF.OL) rose by a staggering 33.14% in 21 sessions from $33.95 to $45.20 at 13:58 EST on Monday, following the last session's downward trend. Oslo Børs All-share Index_GI is dropping 0.89% to $1,365.78, after successive sessions in a row of losses.

About SOLSTAD OFFSHORE

Solstad Offshore ASA operates offshore service and construction vessels for offshore and renewable energy industry worldwide. It provides platform supply vessel, anchor handling vessel, subsea construction, and renewable energy services. The company offers subsea construction and renewable energy services, such as geotechnical work, walk to work services, grouting, SURF operations, deep sea mining, cable laying and repair, trenching and burial, ROV support, installation of subsea equipment, survey work, IMR operations, node seismic operations, and diving and topside maintenance work. It operates a fleet of 25 construction service vessels, 26 anchor handling tug support vessels, and 45 platform supply vessels. The company was founded in 1964 and is headquartered in Skudeneshavn, Norway.

Earnings Per Share

As for profitability, SOLSTAD OFFSHORE has a trailing twelve months EPS of $24773.9.

Volume

Today's last reported volume for SOLSTAD OFFSHORE is 695468 which is 28.71% below its average volume of 975583.

More news about SOLSTAD OFFSHORE (SOFF.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
SOLSTAD OFFSHORE Stock Bullish By 33% In The Last 21 Sessions | ViaNews EU